The role of Fcg receptors in atherosclerosis

Experimental Biology and Medicine

Volumn 237, Issue 6, 2012, Pages 609-616

  Wang, Xinhong ^a   Liu, Xiaojun ^a   Kishimoto, Chiharu ^b   Yuan, Zuyi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; C reactive protein; Fc receptors; Immune complexes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; GELATINASE B; INTERSTITIAL COLLAGENASE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PENTRAXIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ANTIGEN ANTIBODY COMPLEX; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL TYPE; CONFOCAL MICROSCOPY; CORONARY ARTERY ATHEROSCLEROSIS; DENDRITIC CELL; ENDOTHELIUM CELL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MAST CELL; MONOCYTE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALIA;

EID: 84863824614     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.011373     Document Type: Review

References (89)

1. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-91
2. Smith KGC, Clatworthy MR. Fc gamma RIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010;10:328-43
3. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheum 2006;2:99-106
4. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allerg Immun 2009;37:20-8
5. Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Jaakkola O, Jokela H, Ylä-Herttuala S, Luoma JS, Koivula T, Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-7
6. Xu Q, Kiechl S, Mayr M, Metzler B, Egger G, Oberhollenzer F, Willeit J, Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis-clinical significance determined in a follow-up study. Circulation 1999;100:1169-74
7. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004;110:2552-8
8. Lu X, Kakkar V. The role of heat shock protein (HSP) in atherosclerosis: pathophysiology and clinical opportunities. Curr Med Chem 2010;17:957-73
9. Burut DFP, Karim Y, Ferns GAA. The role of immune complexes in atherogenesis. Angiology 2010;61:679-89
10. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010;31:2087-95
11. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47
12. Willcocks LC, Smith KGC, Clatworthy MR. Low-affinity Fcg receptors, autoimmunity and infection. Expert Rev Mol Med 2009;11:e24
13. Nimmerjahn F, Ravetch JV. Fcg Receptors: old friends and new family members. Immunity 2006;24:19-28
14. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000;290:84-9
15. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010;236:265-75
16. Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte-endothelial cell adhesion via Fc gamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006;291:H1170-6
17. Ryu J, Lee CW, Shin JA, Park CS, Kim JJ, Park SJ, Han KH. Fc gamma RIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res 2007;75:555-65
18. Kiener PA, Rankin BM, Davis PM, Yocum SA, Warr GA, Grove RI. Immune-complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995;15:990-9
19. Morganelli PM, Rogers RA, Kitzmiller TJ, Bergeron A. Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG fc receptors. J Lipid Res 1995;36:714-24
20. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997;135:161-70
21. Carvalho MD, Vendrame CM, Ketelhuth DF, Yamashiro-Kanashiro EH, Goto H, Gidlund M. High-density lipoprotein inhibits the uptake of modified low-density lipoprotein and the expression of CD36 and Fc gamma RI. J Atheroscler Thromb 2010;17:844-57
22. Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, Shah N, Cronstein BN, Chan ES, Carsons SE. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med 2009;234:354-60
23. Virella G, Muñoz JF, Galbraith GM, Gissinger C, Chassereau C, Lopes-Virella MF. Activation of human monocyte-derived macrophages by immune-complexes containing low-density-lipoprotein. Clin Immunol Immunopathol 1995;75:179-89
24. Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 1999;19:1600-7
25. Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2000;20:2533-38
26. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83
27. Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, Chait A, Bornfeldt KE. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions-potential role of glucose-oxidized LDL. Diabetes 2004;53:3217-25
28. Deguchi JO, Yamazaki H, Aikawa E, Aikawa M. Chronic hypoxia activates the Akt and beta-catenin pathways in human macrophages. Arterioscler Thromb Vasc Biol 2009;29:1664-70
29. Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, Pentikäinen MO. OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol 2006;26:576-83
30. Luo Y, Pollard JW, Casadevall A. Fc gamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway. J Biol Chem 2010;285:4232-42
31. Alberto MF, Bermejo EI, Lazzari MA. Receptor expression for IgG constant fraction in human umbilical vein endothelial cells. Thromb Res 2000;97:505-11
32. Sumiyoshi K, Mokuno H, Iesaki T, Shimada K, Miyazaki T, Kume A, Kiyanagi T, Kuremoto K, Watanabe Y, Tada N, Daida H. Deletion of the Fc receptors gamma chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet. Cardiovasc Res 2008;80:463-70
33. Nagarajan S. Anti-OxLDL IgG blocks OxLDL interaction with CD36, but promotes Fc gamma R, CD32A-dependent inflammatory cell adhesion. Immunol Lett 2007;108:52-61
34. Sundgren NC, Zhu W, Yuhanna IS, Chambliss KL, Ahmed M, Tanigaki K, Umetani M, Mineo C, Shaul PW. Coupling of Fcg receptor I to Fcg receptor IIB by Src kinase mediates C-reactive protein impairment of endothelial function. Circ Res 2011;109:1132-40
35. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S. Potential role of platelet Fc gamma RIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis 2002;164:261-67
36. El-Shahawy M, Noureddin M, Abdullah H, Mack WJ, Calverley DC. Platelet Fc gamma RIIA receptor surface expression is increased in patients with ESRD and is associated with atherosclerotic cardiovascular events. Am J Kidney Dis 2007;49:127-34
37. Schneider DJ, Taatjes SHS. Augmentation of megakaryocyte expression of Fc gamma RIIa by interferon gamma. Arterioscler Thromb Vasc Biol 2009;29:1138-43
38. Konishi H, Katoh Y, Takaya N, Kashiwakura Y, Itoh S, Ra C, Daida H. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation 2002;105:912-16
39. Taka Takaya N, Katoh Y, Iwabuchi K, Hayashi I, Konishi H, Itoh S, Okumura K, Ra C, Nagaoka I, Daida H. Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor gamma-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2005;39:856-64
40. Nicoletti A, Kaveri S, Caligiuri G, Bariéty J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apoE knockout mice. J Clin Invest 1998;102:910-18
41. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol 2003;285:H899-H906
42. Hernández-Vargas P, Ortiz-Muñoz G, López-Franco O, Suzuki Y, Gallego-Delgado J, Sanjuán G, Lázaro A, López-Parra V, Ortega L, Egido J, Gómez-Guerrero C. Fc gamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Cir Res 2006;99:1188-96
43. Kishimoto C. A novel approach to the suppression of atherosclerosis by Fcgamma receptor blockade. Circ Res 2006;99:1154-5
44. Zhao M, Wigren M, Dunér P, Kolbus D, Olofsson KE, Björkbacka H, Nilsson J, Fredrikson GN. Fcgamma RIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol 2010;184:2253-60
45. Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, Covarrubias R, van Leuven S, Witztum JL, Major AS. The inhibitory Fc gamma RIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice. Atherosclerosis 2011;214:73-80
46. Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, Miller ER, Huber SA, Binder CJ, Witztum JL, Morganelli PM. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res 2010;85: 224-31
47. Gavasso S, Nygård O, Pedersen ER, Aarseth JH, Bleie O, Myhr KM, Vedeler CA. Fc gamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis 2005;180:277-82
48. Karakas M, Hoffmann MM, Vollmert C, Rothenbacher D, Meisinger C, Winkelmann B, Khuseyinova N, Böhm BO, Illig T, März W, Koenig W. Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations. BMC Med Genet 2009;10:46
49. Gardemann A, Horstmann A, Santoso S. Fc gamma RIIa-R131H polymorphism: its impact on coronary heart disease in a German cohort. Thromb Haemost 2003;90:1218-20
50. Mollaki V, Steeds RP, Samani NJ, Channer KS, Daly ME. The Fc gamma RIIa His131Arg polymorphism and its association with myocardial infarction. J Thromb Haemost 2004;2:1014-5
51. Murphy A, White A, Nair R, Kingwell B, Duffy S, Chin-Dusting J, Woollard K. C-reactive protein and Fc gamma RIIa functional polymorphisms are not associated with clinical presentation of stable and unstable angina. Thromb Haemost 2007;97:681-2
52. Pessi T, Eklund C, Huhtala H, Raitakari OT, Juonala M, Kähönen M, Viikari JS, Lehtimäki T, Hurme M. CRP and FCGR2A genes have an epistatic effect on carotid artery intima-media thickness: the Cardiovascular Risk in Young Finns Study. Int J Immunogenet 2009;36:39-45
53. Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, Voll RE, Leusen JH, van de Winkel JG, Daniel WG, Reis A, Garlichs CD. Fc gamma RIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. Atherosclerosis 2009;205:512-6
54. Schneider MP, Leusen JH, Herrmann M, Garlichs CD, Amann K, John S, Schmieder RE. The Fcg receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia. Atherosclerosis 2011;218:411-5
55. van der Meer IM, Witteman JC, Hofman A, Kluft C, de Maat MP. Genetic variation in Fc gamma receptor IIa protects against advanced peripheral atherosclerosis-the Rotterdam Study. Thromb Haemost 2004;92:1273-6
56. Sämpi M, Ukkola O, Päivänsalo M, Kesäniemi YA, Hörkkö S. Early atherosclerosis and IgG(2) to bacteria are associated with Fc gamma RIIa genotype in non-smokers. Eur J Clin Invest 2009;39:517-26
57. Masuda M, Miyoshi H, Kobatake S, Nishimura N, Dong XH, Komiyama Y, Takahashi H. Increased soluble Fc gamma RIIIa(M phi) in plasma from patients with coronary artery diseases. Atherosclerosis 2006;188:377-83
58. Masuda M, Amano K, Hong SY, Nishimura N, Fukui M, Yoshika M, Komiyama Y, Masaki H, Iwasaka T, Takahashi H. Soluble Fc gamma RIIIa(M phi) levels in plasma correlate with carotid maximum intima-media thickness (IMT) in subjects undergoing an annual medical checkup. Mol Med 2008;14:436-42
59. Pfeiffer JR, Howes PS, Waters MA, Hynes ML, Schnurr PP, Demidenko E, Bech FR, Morganelli PM. Levels of expression of Fc gamma receptor IIA (CD32) are decreased on peripheral blood monocytes in patients with severe atherosclerosis. Atherosclerosis 2001;155:211-8
60. Yanaga F, Poole A, Asselin J, Blake R, Schieven GL, Clark EA, Law CL, Watson SP. Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor. Biochem J 1995;311:471-8
61. Saeland E, van Royen A, Hendriksen K, Vilé-Weekhout H, Rijkers GT, Sanders LA, van de Winkel JG. Human C-reactive protein does not bind to Fc gamma RIIa on phagocytic cells. J Clin Invest 2001;107: 641-2
62. Du Clos TW, Mold C, Edberg JC, Kimberly RP. Human C-reactive protein does not bind to Fc gamma RIIa on phagocytic cells-Du Clos et al. reply. J Clin Invest 2001;107:642-3
63. Hundt M, Zielinska SM, Schmidt RE. Lack of specific receptors for C-reactive protein on white blood cells. Eur J Immunol 2001;31:3475-83
64. Manolov DE, Röcker C, Hombach V, Nienhaus GU, Torzewski J. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with Fc gamma RIIa. Arterioscler Thromb Vasc Biol 2004;24:2372-7
65. Röcker C, Manolov DE, Kuzmenkina EV, Tron K, Slatosch H, Torzewski J, Nienhaus GU. Affinity of C-reactive protein toward Fc gamma RI is strongly enhanced by the gamma-chain. Am J Pathol 2007;170:755-63
66. Tron K, Manolov DE, Röcker C, Kächele M, Torzewski J, Nienhaus GU. C-reactive protein specifically binds to Fc gamma receptor type I on a macrophage-like cell line. Eur J Immunol 2008;38:1414-22
67. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of Fc gamma R by innate pentraxins. Nature 2008;456:989-92
68. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hy 2005;14:33-7
69. Crowell RE, Du Clos TW, Montoya G, Heaphy E, Mold C. C-reactive protein receptors on the human monocytic cell-line U-937-evidence for additional binding to fc-gamma-RI. J Immunol 1991;147:3445-51
70. Mold C, Gresham HD, Du Clos TW. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol 2001;166:1200-05
71. Bharadwaj D, Stein MP, Volzer M. The major receptor for C-reactive protein on leukocytes is Fc gamma receptor II. J Exp Med 1999;190:585-90
72. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc gamma RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004;24:61-6
73. Nabata A, Kuroki M, Ueba H, Hashimoto S, Umemoto T, Wada H, Yasu T, Saito M, Momomura S, Kawakami M. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaquere. Atherosclerosis 2008;196:129-35
74. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010;142:273-8
75. Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch J, Jialal I. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol 2006;26:2469-75
76. Kawahara K, Biswas KK, Unoshima M, Ito T, Kikuchi K, Morimoto Y, Iwata M, Tancharoen S, Oyama Y, Takenouchi K, Nawa Y, Arimura N, Jie MX, Shrestha B, Miura N, Shimizu T, Mera K, Arimura S, Taniguchi N, Iwasaka H, Takao S, Hashiguchi T, Maruyama I. C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 2008;17:129-38
77. Devaraj S, Yun JM, Duncan-Staley C, Jialal I. C-reactive protein induces M-CSF release and macrophage proliferation. J Leukocyte Biol 2009;85:262-7
78. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ, Hong MK, Park SW, Park SJ. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004;109:2566-71
79. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005;l25:717-22
80. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008;49:1015-23
81. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by fc gamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005;25:1359-63
82. Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L, Shohet RV, Black S, Salmon JE, Samols D, Karp DR, Thomas GD, Shaul PW. Fc gamma RIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res 2005;97:1124-31
83. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007;43:780-91
84. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells-mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 2008;28:698-704
85. Devaraj S, Dasu MR, Singh U, Rao LV, Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009;203:67-74
86. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol 2008;172:22-30
87. Kishimoto C, Shioji K, Yuan Z. Fcg IIB and cardiovascular inflammatory disease. Circ Res 2006;98:e26
88. Kishimoto C. Immunoglobulin therapy, myocardial diseases and atherosclerosis: recent experimental and clinical studies. Current Cardiol Rev 2007;3:15-21
89. Hillyard DZ, Jardine AG, McDonald KJ, Cameron AJ. Fluvastatin inhibits raft dependent Fc gamma receptor signalling in human monocytes. Atherosclerosis 2004;172:219-28